In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
News|Podcasts|March 6, 2026
ACT Brief: Bayesian Methods Drive Adaptive Trials, Digital Endpoints Standardized, FDA Enforces GLP-1 Marketing
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore how Bayesian approaches are powering studies in rare disease and pediatrics, a major public-private initiative is standardizing digital endpoints for regulatory acceptance, and the FDA intensifies enforcement against misleading GLP-1 marketing.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a continuing video
interview , David Morton, PhD, director of biostatistics at Certara, discussed where Bayesian methods are delivering impact in rare diseases and small populations. These approaches allow researchers to borrow from historical or external controls, and hierarchical models enable information-sharing across disease subtypes in basket trials and pediatric extrapolation. - A public-private
partnership showcased at Pfizer and J&J's Digital Implementation Summit demonstrated how consolidated evidence and standardized terminology are accelerating regulatory-ready digital endpoints. Led by Bayer, Pfizer, and DEEP Measures, the Foundational Content Consolidation project mapped novel digital endpoints across physical activity, sleep, cognition, and speech, creating measurement standards and establishing a shared platform to reduce duplicated validation work. - On March 3, the FDA
issued 30 warning letters to telehealth organizations marketing compounded semaglutide and tirzepatide in a proactive crackdown on GLP-1 advertising. Commissioner Marty Makary emphasized that compounded drugs cannot claim equivalence to FDA-approved products or obscure their sourcing, reflecting a broader shift toward ensuring fair balance of risks and benefits in all promotional content.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5